PPL ties up gene technology
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.PPL ties up gene technology
PPL Therapeutics, the biotechnology company behind Dolly the sheep (pictured left), has signed a deal giving it exclusive world-wide rights to the technology used in its gene implanting technology. The agreement with the Roslin Institute in Edinburgh should enable PPL to produce a wider range of therapeutic products using its nuclear transfer technology. The technique involves introducing copies of human genes into animals to produce proteins in their milk. One of the big potential markets is the transgenic production of human serum albumin, a protein used to aid blood transfusions, said to be worth several billion dollars a year.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments